Bioceros Announces Expansion of the Research License Agreement with Crucell on STAR Technology

03-May-2011 - Netherlands

Bioceros B.V. announced the extension of the non-exclusive STAR® research license agreement with Crucell. The license agreement with the Netherlands based company Bioceros covers the production of monoclonal antibodies. In addition, the extension of the agreement now includes the right for Bioceros B.V. to sub-license and independently market the STAR® technology to third parties. Financial details of the agreement were not disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous